[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The infant has d-TGA with intact ventricular septum and a restrictive PFO, leading to severe hypoxemia unresponsive to prostaglandin.  \nBalloon atrial septostomy (Rashkind procedure) is the standard immediate intervention to improve atrial-level mixing when prostaglandins alone are insufficient and the patient is stable but severely hypoxemic.  \nThis is preferred before surgical options if anatomy is suitable.  \n\nThe answer is B"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-002", "question": "A 58-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab presents with 6 weeks of progressive dyspnea and dry cough. HRCT shows diffuse ground-glass opacities with areas of consolidation in a peribronchovascular distribution. Bronchoalveolar lavage reveals 45% lymphocytes with CD4/CD8 ratio of 0.5. Methotrexate pneumonitis is suspected. Which histopathologic pattern is most commonly associated with methotrexate-induced lung toxicity?", "options": ["Usual interstitial pneumonia", "Diffuse alveolar damage", "Hypersensitivity pneumonitis pattern", "Organizing pneumonia", "Pulmonary alveolar proteinosis"], "answer": "C", "answer_index": 2, "explanation": "Methotrexate-induced lung toxicity most commonly manifests as a hypersensitivity pneumonitis pattern, characterized by lymphocytic alveolitis with low CD4/CD8 ratio, granulomas, and interstitial inflammation. The BAL findings of elevated lymphocytes with inverted CD4/CD8 ratio support this diagnosis. While organizing pneumonia and diffuse alveolar damage can occur, hypersensitivity pneumonitis is the predominant pattern. UIP pattern is more characteristic of RA-ILD itself rather than drug toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Methotrexate-induced lung toxicity most commonly presents with a histopathologic pattern of **organizing pneumonia** (also known as bronchiolitis obliterans organizing pneumonia, or BOOP pattern), often accompanied by interstitial inflammation and granulomas in some cases.  \n\nThe answer is (D)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient has severe preeclampsia, which is characterized by systemic endothelial dysfunction leading to increased capillary permeability.  \nPulmonary edema in preeclampsia often occurs even with normal or low filling pressures (CVP 4 mmHg here), preserved ejection fraction, and diastolic dysfunction.  \nThe elevated E/e′ indicates increased left ventricular filling pressures, but the primary driver of pulmonary edema in preeclampsia is often **capillary leak** due to endothelial injury, not just diastolic dysfunction alone.  \nDiastolic dysfunction is common in preeclampsia due to myocardial edema and afterload increase, but the question asks for the **best** pathophysiologic mechanism given the clinical picture: low CVP, preserved EF, and severe preeclampsia—pointing to permeability edema from endothelial dysfunction.  \n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-004", "question": "A 67-year-old man with ischemic cardiomyopathy (EF 25%) and cardiac resynchronization therapy-defibrillator presents after appropriate ICD shock for ventricular tachycardia. He is on maximally tolerated guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Electrophysiology study reveals scar-related reentrant VT from the inferolateral left ventricle. Catheter ablation is performed. Three months later, he has recurrent VT storm despite amiodarone. Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?", "options": ["Mexiletine", "Sotalol", "Ranolazine", "Quinidine", "Dofetilide"], "answer": "A", "answer_index": 0, "explanation": "Mexiletine, a class IB sodium channel blocker, when added to amiodarone in patients with recurrent VT despite amiodarone monotherapy, has shown reduction in VT recurrence and ICD shocks. The MEXICA trial demonstrated this combination's efficacy. Sotalol and dofetilide have proarrhythmic risks in low EF patients. Quinidine has significant toxicity and limited modern data. Ranolazine has some antiarrhythmic properties but lacks robust evidence in scar-related VT. Mexiletine's synergistic sodium channel blockade with amiodarone provides additional substrate modification.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has ischemic cardiomyopathy with recurrent VT storm despite guideline-directed medical therapy, CRT-D, catheter ablation, and amiodarone.  \nAmong the options, **ranolazine** has shown evidence in reducing ventricular arrhythmias in ischemic cardiomyopathy and has been associated with improved outcomes in some studies, though its mortality benefit specifically in this refractory VT population is more limited compared to other interventions. However, in trials such as the MERLIN-TIMI 36, ranolazine reduced certain arrhythmias in patients with non-ST-elevation ACS, and subsequent studies in structural heart disease suggest antiarrhythmic effects.  \n\nThe other options:  \n- **Mexiletine** is used as add-on therapy for VT but has not shown mortality benefit.  \n- **Sotalol** and **dofetilide** are antiarrhythmics with proven efficacy in suppressing VT but without proven mortality benefit in this specific refractory VT storm setting.  \n- **Quinidine** is used for Brugada syndrome or idiopathic VF, not for scar-related VT in ischemic cardiomyopathy with mortality benefit.  \n\nGiven the question asks for **additional pharmacologic therapy with demonstrated mortality benefit in this specific population**, none have strong mortality data in refractory VT storm, but ranolazine has the most evidence for reducing arrhythmic events with possible outcome benefits in ischemic cardiomyopathy patients.  \n\nThe answer is C."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This presentation is classic for **PFAPA syndrome** (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis).  \nGenetic testing for other periodic fever syndromes is negative, episodes are regular, and the child is well between episodes.  \nIn PFAPA, **tonsillectomy (with or without adenoidectomy)** is often curative and can induce complete remission, especially in cases with prominent pharyngitis/tonsillitis.  \nWhile corticosteroids at episode onset can abort attacks, they do not induce complete remission. Colchicine, anakinra, and cimetidine are not first-line curative treatments for PFAPA.  \n\nThe answer is D"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-006", "question": "A 45-year-old woman with systemic lupus erythematosus develops acute kidney injury with serum creatinine rising from 1.0 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous RBC casts, and dysmorphic red cells. Complement levels are low. Kidney biopsy reveals diffuse proliferative glomerulonephritis (Class IV-G) with 40% cellular crescents, wire loop lesions, and activity index of 14/24 with chronicity index of 2/12. Anti-dsDNA antibody titer is markedly elevated. Which induction regimen has demonstrated superior renal response rates in this clinical scenario?", "options": ["Mycophenolate mofetil plus glucocorticoids", "Cyclophosphamide (Euro-Lupus protocol) plus glucocorticoids", "Voclosporin plus mycophenolate mofetil plus glucocorticoids", "Rituximab plus mycophenolate mofetil plus glucocorticoids", "Belimumab plus cyclophosphamide plus glucocorticoids"], "answer": "C", "answer_index": 2, "explanation": "The AURORA trial demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and glucocorticoids alone in active lupus nephritis. This triple therapy showed benefit across Class III, IV, and V lupus nephritis. While MMF and cyclophosphamide are established induction agents, the addition of voclosporin (a novel calcineurin inhibitor) provides superior efficacy. Rituximab and belimumab combinations lack the same level of evidence for superior renal response in this setting.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has active, severe lupus nephritis (Class IV-G with crescents) requiring aggressive induction therapy.  \n\nBased on current evidence, for proliferative lupus nephritis, **mycophenolate mofetil (MMF) plus glucocorticoids** and **cyclophosphamide plus glucocorticoids** have been established as effective induction regimens.  \nHowever, recent randomized controlled trials (such as AURORA and AURORA 2) have shown that adding **voclosporin** to MMF and glucocorticoids results in superior renal response rates compared to MMF and glucocorticoids alone.  \n\nGiven the question specifically asks for the regimen with demonstrated superior renal response rates in this clinical scenario, the evidence supports **voclosporin + MMF + glucocorticoids** as the best choice among the options.  \n\nThe answer is (C)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-007", "question": "A 72-year-old man is admitted to the ICU with septic shock from pneumonia. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, MAP remains 58 mmHg. Echocardiography shows hyperdynamic left ventricle with EF 75%, small LV cavity, and IVC diameter of 0.8 cm with >50% respiratory variation. Lactate is 6.2 mmol/L. Which vasopressor strategy is most appropriate?", "options": ["Add vasopressin 0.03 units/min", "Add epinephrine infusion", "Add phenylephrine infusion", "Add angiotensin II infusion", "Increase norepinephrine to maximum dose before adding second agent"], "answer": "A", "answer_index": 0, "explanation": "Current sepsis guidelines recommend adding vasopressin (up to 0.03 units/min) as the second-line vasopressor when norepinephrine fails to achieve target MAP, typically when norepinephrine exceeds 0.25-0.5 mcg/kg/min. Vasopressin acts via V1 receptors independent of catecholamine pathways, which may be downregulated in sepsis. The VASST trial showed potential mortality benefit in less severe septic shock. The echocardiographic findings suggest adequate volume status (small IVC with variation indicates fluid responsiveness is exhausted). Angiotensin II is reserved for refractory vasodilatory shock after multiple agents. Phenylephrine may reduce cardiac output.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient has septic shock with persistent hypotension despite norepinephrine. The echocardiogram shows a hyperdynamic left ventricle with a small LV cavity and a very low IVC diameter with high respiratory variation, indicating significant volume depletion (low preload) despite ongoing shock and high lactate.  \n\nIn this setting, the primary issue appears to be inadequate preload (low IVC diameter with high variation) rather than pure vasoplegia, so adding another vasopressor without addressing volume could worsen organ perfusion. However, the question asks for the most appropriate **vasopressor strategy** given that MAP remains low after initial norepinephrine.  \n\nCurrent guidelines recommend adding a second vasopressor (typically vasopressin) when norepinephrine requirements are moderate to high to help achieve target MAP and reduce norepinephrine dose. Here, norepinephrine is at 0.5 mcg/kg/min, which is a moderate dose.  \n\nOption A (add vasopressin 0.03 units/min) is guideline-concordant for septic shock when MAP remains below target despite initial norepinephrine, and it may help reduce norepinephrine requirements.  \n\nThe other options are less appropriate:  \n- Epinephrine (B) is usually reserved for refractory shock or as first-line in anaphylaxis or certain cardiogenic shock.  \n- Phenylephrine (C) is pure alpha-agonist and not recommended as first add-on in septic shock.  \n- Angiotensin II (D) is considered in refractory shock after vasopressin.  \n- Increasing norepinephrine to maximum (E) before adding a second agent is not consistent with current early-additive approach.  \n\nGiven the clinical scenario, adding vasopressin is the most appropriate next step in vasopressor strategy.  \n\nThe answer is A"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-008", "question": "A 29-year-old primigravida at 34 weeks gestation presents with sudden-onset severe headache and right-sided weakness. Blood pressure is 178/112 mmHg. CT head shows left parietal intracerebral hemorrhage with surrounding edema. MRV demonstrates absence of flow in the superior sagittal sinus and left transverse sinus consistent with cerebral venous thrombosis. Platelet count is 82,000/μL, LDH is elevated, and peripheral smear shows schistocytes. Which is the most appropriate immediate management?", "options": ["Emergent cesarean delivery followed by therapeutic anticoagulation", "Therapeutic anticoagulation with unfractionated heparin", "Platelet transfusion followed by decompressive craniectomy", "Plasma exchange followed by anticoagulation", "Magnesium sulfate and antihypertensives with delayed anticoagulation"], "answer": "A", "answer_index": 0, "explanation": "This patient has cerebral venous thrombosis complicated by hemorrhagic transformation in the setting of HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) evidenced by thrombocytopenia, elevated LDH, and schistocytes. The definitive treatment for HELLP is delivery. While anticoagulation is standard for CVT even with hemorrhage, the underlying HELLP syndrome will not resolve without delivery and may worsen, increasing bleeding risk. Emergent cesarean delivery addresses the root cause, after which therapeutic anticoagulation can be safely initiated. Plasma exchange is for TTP, not HELLP. Delaying anticoagulation without addressing HELLP is inappropriate.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Let’s break this down step by step.  \n\nThe patient is 34 weeks pregnant with:  \n- Sudden severe headache, right-sided weakness  \n- BP 178/112 → severe hypertension  \n- CT head: left parietal ICH with edema  \n- MRV: cerebral venous thrombosis (CVT) in superior sagittal sinus and left transverse sinus  \n- Labs: thrombocytopenia (82,000/μL), elevated LDH, schistocytes → features of microangiopathic hemolytic anemia  \n\nThis combination in pregnancy suggests **thrombotic thrombocytopenic purpura (TTP)** or possibly **HELLP syndrome**.  \nKey point: CVT + thrombocytopenia + schistocytes + neurological symptoms in pregnancy → TTP is a strong possibility because TTP is associated with CVT and requires urgent plasma exchange.  \n\nIn TTP with thrombosis (including CVT), the immediate lifesaving treatment is **plasma exchange** to remove ADAMTS13 autoantibodies and replenish the enzyme. Anticoagulation may be considered after starting plasma exchange for the CVT, but plasma exchange is first-line.  \n\nOption D says: **Plasma exchange followed by anticoagulation** — this matches the priority for suspected TTP with CVT.  \n\nOther options:  \n- A: Emergent delivery before stabilizing TTP could worsen outcome; delivery does not treat TTP acutely.  \n- B: Starting heparin without addressing TTP first risks worsening thrombotic microangiopathy.  \n- C: Platelet transfusion in TTP is relatively contraindicated (can worsen thrombosis); craniectomy may be needed for ICH with herniation, but not indicated yet here.  \n- E: MgSO₄ and antihypertensives treat preeclampsia/HELLP, but schistocytes + severe thrombocytopenia + CVT point more to TTP; delayed anticoagulation could allow CVT extension.  \n\nGiven the exam question’s data, the most appropriate **immediate management** is plasma exchange.  \n\nThe answer is D  \n\n**The answer is D**"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-009", "question": "A 14-year-old girl presents with 3 months of progressive fatigue, arthralgia, and facial rash. Laboratory evaluation reveals ANA 1:1280 (homogeneous pattern), anti-dsDNA positive, anti-Smith positive, C3 45 mg/dL (normal 90-180), C4 6 mg/dL (normal 10-40), and anti-C1q antibodies positive. Urinalysis shows 2+ protein and 10-15 RBCs/hpf. She is diagnosed with juvenile-onset systemic lupus erythematosus. The presence of anti-C1q antibodies in this patient most specifically predicts which disease manifestation?", "options": ["Neuropsychiatric lupus", "Proliferative lupus nephritis", "Antiphospholipid syndrome", "Lupus pneumonitis", "Autoimmune hemolytic anemia"], "answer": "B", "answer_index": 1, "explanation": "Anti-C1q antibodies have the highest specificity for lupus nephritis, particularly proliferative forms (Class III/IV). Studies demonstrate that anti-C1q antibodies have a negative predictive value approaching 100% for active renal disease-their absence essentially excludes active nephritis. The combination of anti-C1q with anti-dsDNA antibodies and low complement strongly predicts proliferative nephritis. While anti-C1q can be seen in hypocomplementemic urticarial vasculitis, in SLE context, they specifically correlate with renal involvement. Anti-ribosomal P antibodies are more associated with neuropsychiatric lupus.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Anti-C1q antibodies are strongly associated with lupus nephritis, particularly proliferative forms (class III and IV). Their presence increases the specificity for renal involvement, especially when combined with low complement levels and anti-dsDNA antibodies, as seen in this case with active urinary sediment and low C3/C4.  \n\nThe answer is B"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-010", "question": "A 52-year-old man with no prior cardiac history presents with acute anterior STEMI. Primary PCI reveals 100% occlusion of the proximal LAD with TIMI 0 flow. After successful stenting with TIMI 3 flow restoration, he develops cardiogenic shock with blood pressure 78/52 mmHg, heart rate 112 bpm, and cardiac index 1.6 L/min/m². Echocardiography shows akinesis of the anterior wall, apex, and septum with EF 20%. He is started on norepinephrine and dobutamine. Despite escalating support, he remains in refractory shock. Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?", "options": ["Intra-aortic balloon pump", "Impella CP", "TandemHeart", "Veno-arterial ECMO", "Impella 5.5"], "answer": "E", "answer_index": 4, "explanation": "Impella 5.5 provides up to 5.5 L/min of forward flow and the greatest degree of LV unloading among the options by actively aspirating blood from the LV and ejecting it into the ascending aorta. This reduces LV end-diastolic pressure, wall stress, and myocardial oxygen demand while maintaining systemic perfusion. VA-ECMO provides excellent systemic support but increases LV afterload and may worsen pulmonary edema without LV venting. TandemHeart provides good support but requires transseptal puncture. Impella CP provides only 3-4 L/min. IABP provides modest afterload reduction with minimal flow augmentation (0.5 L/min).", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The question asks for the mechanical circulatory support device that provides the **greatest degree of left ventricular unloading** in a patient with refractory cardiogenic shock after anterior STEMI.  \n\n- **Intra-aortic balloon pump (IABP)** provides modest afterload reduction and improves coronary perfusion but offers minimal direct ventricular unloading.  \n- **Impella CP** (percutaneous, up to 3.5–4.0 L/min flow) unloads the LV by pumping blood from the LV into the aorta.  \n- **TandemHeart** provides left atrial-to-femoral artery bypass (requires transseptal puncture), can provide higher flows (up to 5 L/min), and unloads the LV well.  \n- **Veno-arterial ECMO** provides full cardiopulmonary support but increases LV afterload unless combined with an additional venting strategy; by itself, it does not unload the LV as effectively as devices that directly decompress the LV.  \n- **Impella 5.5** provides up to 5.5 L/min flow and more LV unloading than Impella CP, but is still an axial flow pump from LV to aorta.  \n\nAmong these, **TandemHeart** (when considering purely the degree of LV unloading) provides greater volume unloading of the left ventricle than Impella devices because it bypasses the LV entirely (left atrium to artery), reducing LV preload more effectively. However, in clinical practice, Impella 5.5 also offers significant unloading, but TandemHeart is often cited in studies as providing superior decompression.  \n\nFor the specific question of **greatest degree of left ventricular unloading**, the best answer is **TandemHeart**.  \n\nThe answer is (C)"}]